VIJAYAVijaya Diagnostic Centre Ltd.
Vijaya Diagnostic Centre Q2 FY27 Results: Consolidated Net Profit ₹59.47 Crore on Total Income of ₹260 Crore
- Earnings
- diagnostic services
Reviewed byKeshav SehgalBlacklitt Research
Vijaya Diagnostic Centre (NSE: VIJAYA) reported consolidated total income of ₹260.34 crore and net profit of ₹59.47 crore for the quarter ended 30 Sep 2026, it said in a filing on 03 Nov 2026. On a standalone basis, total income was ₹247.45 crore and net profit ₹57.92 crore.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹260.34 crore, up 25.3% YoY and 8.7% QoQ
- Net profit: ₹59.47 crore, up 37.4% YoY and 12.0% QoQ
- EPS: ₹5.78 basic, against ₹4.21 a year earlier
- Finance costs: ₹11.38 crore, up 45.4% YoY
Standalone
The company on its own, without its subsidiaries
- Total income: ₹247.45 crore, up 26.8% YoY and 8.7% QoQ
- Net profit: ₹57.92 crore, up 34.8% YoY and 9.0% QoQ
- EPS: ₹5.63 basic, against ₹4.18 a year earlier
- Finance costs: ₹10.42 crore, up 44.4% YoY
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 260.34 | 207.81 | +25.3% | 239.51 | +8.7% | |
| Revenue from operations | 255.39 | 201.56 | +26.7% | 230.98 | +10.6% |
| Other income | 4.95 | 6.25 | -20.8% | 8.53 | -42.0% |
| 59.47 | 43.28 | +37.4% | 53.10 | +12.0% | |
| Profit before tax | 79.42 | 57.98 | +37.0% | 70.94 | +11.9% |
| Finance costs | 11.38 | 7.83 | +45.4% | 11.00 | +3.4% |
| Depreciation | 26.90 | 22.27 | +20.8% | 25.12 | +7.1% |
| Tax expense | 19.94 | 14.70 | +35.7% | 17.84 | +11.8% |
| Net profit margin | 22.84% | 20.83% | +2.02 pp | 22.17% | +0.67 pp |
| EPS, basic (₹) | 5.78 | 4.21 | +37.3% | 5.16 | +12.0% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit grew faster than total income. Consolidated total income rose 25.3% to ₹260.34 crore from ₹207.81 crore a year earlier, while net profit rose 37.4% to ₹59.47 crore. Revenue from operations of ₹255.39 crore grew 26.7%, and other income fell 20.8% to ₹4.95 crore.
Operations make up most of the income. Other income was 1.9% of consolidated total income this quarter, against 3.0% a year earlier (₹6.25 crore of ₹207.81 crore), and 6.2% of profit before tax of ₹79.42 crore.
Finance costs rose faster than income. They reached ₹11.38 crore, or 4.4% of total income, against 3.8% a year earlier, and depreciation rose 20.8% to ₹26.90 crore over the same comparison.
Tax expense was ₹19.94 crore, 25.1% of profit before tax, against 25.4% in the year-earlier quarter (₹14.70 crore of ₹57.98 crore). The results restate prior periods for the amalgamation of Medinova Diagnostic Services Limited under an NCLT order dated 13 Oct 2025; the auditors' conclusion on the consolidated results is unmodified.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 247.45 | 195.13 | +26.8% | 227.56 | +8.7% | |
| Revenue from operations | 242.00 | 189.96 | +27.4% | 218.54 | +10.7% |
| Other income | 5.45 | 5.17 | +5.4% | 9.02 | -39.6% |
| 57.92 | 42.98 | +34.8% | 53.15 | +9.0% | |
| Profit before tax | 77.93 | 57.47 | +35.6% | 70.92 | +9.9% |
| Finance costs | 10.42 | 7.21 | +44.4% | 10.82 | -3.7% |
| Depreciation | 22.33 | 19.40 | +15.1% | 23.99 | -6.9% |
| Tax expense | 20.00 | 14.49 | +38.0% | 17.77 | +12.6% |
| Net profit margin | 23.41% | 22.02% | +1.38 pp | 23.36% | +0.05 pp |
| EPS, basic (₹) | 5.63 | 4.18 | +34.7% | 5.17 | +8.9% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 34.8% to ₹57.92 crore, slower than the 35.6% rise in profit before tax to ₹77.93 crore, while total income rose 26.8% to ₹247.45 crore. Revenue from operations grew 27.4%, faster than other income, which rose 5.4% to ₹5.45 crore.
Standalone tax expense of ₹20.00 crore was 25.7% of profit before tax, and finance costs of ₹10.42 crore were 4.2% of total income. Consolidated total income is ₹12.89 crore higher than standalone, and consolidated net profit is ₹1.55 crore higher.
Inference
Shareholders approved it at the annual general meeting on 24 Sep 2026, and it was paid on 07 Oct 2026. The cash flow statement shows ₹20.60 crore transferred to an earmarked account for it.
The company issued 1,00,987 equity shares on exercise of employee stock options in the quarter and year to date, and granted 2,69,500 options under ESOP 2018 in the year to date. The notes do not give the reason for the rise in finance costs or in employee benefits expense, or how the slump sale of the Medinova Millennium MRI Services LLP business affects the quarter's figures.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
